AFFiRiS

Focus: AFFiRiS is an Austrian biotech company specializing in therapeutic vaccines, with a focus on neurodegenerative diseases and metabolic disorders. The company operates as a public-stage entity with a diversified pipeline but no marketed products to date.

Infectious Diseases Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About AFFiRiS

AI assessmentNot Hiring

No open roles listed right now. Follow AFFiRiS to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

20 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease

Alzheimer´s Disease

N/A

Clinical Trials (1)

NCT01357629Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease

N/A

Help build intelligence for AFFiRiS

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneer a novel vaccine modality (AFFITOPE) targeting high-unmet-need neurodegenerative diseases with multiple Phase 1/2 programs in Alzheimer's and Parkinson's
Join a lean, focused organization (Vienna-based) with a 19-year track record in translating innovative immunology into clinical candidates
Exposure to emerging therapeutic areas (metabolic disease, neuroinflammation) with early-stage pipeline optionality across 8 distinct programs

Watch Out For

Early-stage pipeline (12 Phase 1, 2 Phase 2, 0 Phase 3) with no marketed revenue or approved drugs, limiting near-term commercial visibility and job stability
Currently zero active job openings and undisclosed financial metrics (funding, revenue, R&D spend, cash position) create opacity around runway and hiring capacity
Emerging neurodegenerative vaccine space carries high clinical and regulatory risk; multiple Phase 1 programs suggest early-stage learning curve rather than validation

Generated by Claude from AFFiRiS's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

AFF008E: Observational Phase 1b Follow-up Extension Study for Patients With Parkinson's Disease Afte

Parkinson's Disease

N/A

Clinical Trials (1)

NCT01885494AFF008E: Observational Phase 1b Follow-up Extension Study for Patients With Parkinson's Disease After Immunization With AFFITOPE® PD01A

N/A

AD01 Follow up Extension Visit

Alzheimer´s Disease

N/A

Clinical Trials (1)

NCT01225809AD01 Follow up Extension Visit

N/A

Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied Duri

Alzheimer's Disease

N/A

Clinical Trials (1)

NCT01568086Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A

N/A

AFFITOPE AT04A

Hypercholesterolemia

Phase 1

AFFITOPE AT06A

Hypercholesterolemia

Phase 1

AFFITOPE® PD01A

Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT02216188Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity

Phase 1

AFFITOPE® PD01A

Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT01568099Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Disease

Phase 1

AFFITOPE® PD01A + Adjuvant

Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT02758730Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients

Phase 1

AFFITOPE® PD01A

Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT02618941Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA)

Phase 1

Low dose AFFITOPE® PD03A + Adjuvant

Parkinson Disease

Phase 1

Clinical Trials (1)

NCT02267434Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease

Phase 1

AFFITOPE® AT04A+adjuvant

Hypercholesterolemia

Phase 1

Clinical Trials (1)

NCT02508896Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects

Phase 1

AFFITOPE® PD01A + Adjuvant

Multiple System Atrophy

Phase 1

Clinical Trials (1)

NCT02270489Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA

Phase 1

ATH03

HDL

Phase 1

Clinical Trials (1)

NCT01284582Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)

Phase 1

AFFITOPE AD03

Alzheimer's Disease

Phase 1

Clinical Trials (1)

NCT01309763Safety and Tolerability of AFFITOPE AD03

Phase 1

AFFITOPE PD01A

Parkinson's Disease

Phase 1

AFFITOPE PD03A

Parkinson's Disease

Phase 1

AFFITOPE AD01

Alzheimer's Disease

Phase 1

Clinical Trials (2)

NCT00495417Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease

Phase 1

NCT00711139Long-term Safety and Tolerability of AFFITOPE AD01

N/A

AFFITOPE® AD02

Alzheimer´s Disease

Phase 2

Clinical Trials (1)

NCT02008513Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006

Phase 2

AFFITOPE AD02

Alzheimer's Disease

Phase 2

Clinical Trials (4)

NCT01117818Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Phase 2

NCT01093664Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02

Phase 1

NCT00633841Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease

Phase 1

+1 more

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2005

Portfolio: 20 clinical trials

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

17 pipeline

Marketed

Pipeline